Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 12/20 | 0.71 |
| ▸ | ESRRG | P62508 | 6/20 | 0.71 |
| ▸ | EBP | Q15125 | 5/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.69 |
| ▸ | DRD3 | P35462 | 3/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906173 | 1.00 | HTR6 (0.77) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL8140749 | 0.94 | ESR1 (0.74) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL9451187 | 0.90 | ESR1 (0.72) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL9451189 | 0.90 | ESR1 (0.72) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL14044785 | 0.90 | ESR1 (0.71) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL22022384 | 0.89 | HTR6 (0.61) | HTR6LMNAESR1ESRRGEBP | |
| Toremifene SCHEMBL906278 | 0.87 | HTR6 (1.00) | HTR6LMNAESR1ESRRGEBP | |
| Toremifene SCHEMBL7465 | 0.87 | HTR6 (1.00) | HTR6LMNAESR1ESRRGEBP | |
| Toremifene SCHEMBL1152000 | 0.87 | HTR6 (1.00) | HTR6LMNAESR1ESRRGEBP | |
| SCHEMBL17164682 | 0.87 | ESR1 (0.79) | HTR6LMNAESR1ESRRGEBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-23 | — | — | US | claimed |
| US-20040092602-A1 | Administering toremifene | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-05-13 | — | — | US | claimed |
| US-6413535-B1 | ADMINISTERING CHLORINATED PHENYL COMPOUND | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-07-02 | — | — | US | claimed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | claimed |
| EP-2277514-A1 | A method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2011-01-26 | — | — | EP | disclosed |
| EP-1771179-A2 | COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF | GTX, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-12-21 | — | — | US | disclosed |
| WO-2006010162-A2 | COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS, AND SERMs AND METHODS OF USE THEREOF | GTX, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060019989-A1 | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof | GTX, INC | 2006-01-26 | — | — | US | disclosed |
| EP-1003496-B1 | MEDICAMENT FOR TREATING PROSTATE INTRAEPITHELIAL NEOPLASIA | UNIV TENNESSEE RES CORP (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-23 | — | — | US | disclosed |
| US-20040176470-A1 | suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-09-09 | — | — | US | disclosed |
| US-6413533-B1 | ADMINISTERING ANTIESTROGEN | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-07-02 | — | — | US | disclosed |
| US-6410043-B1 | Method for chemoprevention of prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-06-25 | — | — | US | disclosed |
| EP-1003496-A1 | METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999056739-A1 | A METHOD FOR CHEMOPREVENTION OF PROSTATE CANCER | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5491173-A | ESTROGENIC, ANTIESTROGENIC AGENTS, ANTITUMOR AGENTS | ORION-YHTYMA OY (FI) | 1996-02-13 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176470-A1 | suppressing, inhibiting, or reducing the incidence of pre-malignant lesions of prostate cancer | ACP3, KLK3, MKI67 | HTR6 3810/4885LMNA 215/4885ESR1 253/4885 |
| US-20040186185-A1 | Using toremifene and/or analog or metabolite; reducing incidence of premalignant lesions | AR, OPRL1, NR5A1 | HTR6 981/4885LMNA 547/4885ESR1 19/4885 |
| US-20060287400-A1 | benign prostatic hyperplasia, prostate intraepithelial neoplasia (PIN), or an abnormally high level of circulating prostate specific antibody (PSA), | KLK3, ACP3, BPHL | HTR6 4727/4885LMNA 297/4885ESR1 767/4885 |
| US-20060019989-A1 | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof | NR5A1, SRD5A1, CYP19A1 | HTR6 382/4885LMNA 1911/4885ESR1 62/4885 |
| US-20040092602-A1 | Administering toremifene | OPRL1, OPRK1, NR5A1 | HTR6 825/4885LMNA 472/4885ESR1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.